The Alatech condom trial is the first of more than 25 manufacturing evaluation trials of Vytex(TM) NRL to progress this far. Most recently, successful manufacturing trials of the first low-ammonia version of Vytex(TM) NRL have been completed.
At the same time, the company is marketing Vytex(TM) NRL globally to all industries that use natural rubber latex or synthetic substitutes in their products. This includes the healthcare industry (surgical and exam gloves, catheters, probe covers, etc.), condom manufacturers, the foam industry and mattress manufacturers, the threads industry and clothing manufacturers, the adhesives industry, the balloon industry and others.
Vystar is the exclusive creator of the proprietary technology to produce Vytex(TM) NRL, a standardized NRL source material that is refined to significantly reduce the antigenic protein content to as low as undetectable levels in liquid NRL and finished latex products. This is important because latex allergy has become an increasing concern for everyone from healthcare workers to children to condom users. It is estimated that as many as 17 percent of healthcare workers (because of prolonged and/or repeated contact with latex) and 3 percent of the general population could have an allergic reaction to the protein in NRL. However, because of its superior properties -- such as barrier protection, the absence of carcinogens, strength and durability, fit and comfort, memory, elasticity, low cost, and minimal environmental impact -- latex is the ingredient of choice for a vast array of everyday products. In fact, Vytex(TM) NRL opens the door to widespread use of NRL in some 40,000 products.
About Vystar Corporation: Vystar Corporation, incorporated in 2003, is
a privately funded corpora
|SOURCE Vystar Corporation|
Copyright©2008 PR Newswire.
All rights reserved